Nautilus CEO granted 650,000 stock options

Nautilus Biotechnology CEO Sujal M. Patel received a grant of 650,000 stock options described as a right to buy shares at an exercise price of $0.0000 per share.

Rhea-AI Filing Summary

Nautilus Biotechnology CEO Sujal M. Patel received a grant of 650,000 stock options described as a right to buy shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the options vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on his continued service.

Insider Trade Summary

Grant/Award: 650,000 shares

Grant/Award 1 txn

Insider Patel Sujal M

Role CEO, President, and Secretary

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	650,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 650,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nautilus Biotechnology (NAUT) report for Sujal Patel?

Nautilus Biotechnology reported that CEO Sujal M. Patel received a grant of 650,000 stock options. These options are a right to buy company shares and represent equity-based compensation tied to his ongoing role and service with the company.

How many stock options were granted to Nautilus (NAUT) CEO Sujal Patel?

Sujal M. Patel was granted 650,000 stock options. This award increases his potential future ownership in Nautilus Biotechnology, aligning his compensation with shareholder interests through equity that vests over time based on continued service.

What is the exercise price of Sujal Patel’s Nautilus (NAUT) stock options?

The stock options granted to Sujal M. Patel carry an exercise price of $0.0000 per share. This effectively makes the options deeply in-the-money once vested, serving as a strong long-term equity incentive linked to his continued employment.

When do Sujal Patel’s Nautilus (NAUT) stock options start vesting?

The options begin vesting from a vesting commencement date of January 1, 2026. Twenty-five percent vest on the one-year anniversary of that date, with the remaining balance vesting monthly over the following three years, subject to continued service.

What are the vesting terms for the 650,000 Nautilus (NAUT) stock options granted to Sujal Patel?

Twenty-five percent of the options vest on the one-year anniversary of January 1, 2026. The remaining shares vest in equal monthly installments over 36 months, contingent on Patel maintaining continuous status as a service provider to Nautilus.

Is Sujal Patel’s Nautilus (NAUT) stock option grant contingent on continued service?

Yes, vesting of Sujal Patel’s stock options is conditioned on his continuous status as a service provider. If he remains in service, portions vest after one year from January 1, 2026, and then monthly over the following three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:31 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sujal M

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	03/02/2026		A		650,000		(1)	03/02/2036	Common Stock	650,000	$0	650,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

Remarks:

	/s/ Mathew B. Murphy, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.